Advances in effects of tyrosine kinase inhibitors on QT interval and its clinical significance

Abstract

Abstract:

Tyrosine kinase inhibitors (TKIs) are typically used as novel anti-tumor drugs, which have been widely applied to clinical treatments in recent years. Clinical trials have demonstrated that these drugs are effective in the treatment of various cancers. TKIs have also been reported to affect the QT interval, but the effects are not the same in different drug treatments. Therefore, each TKI has different warnings,precautions, and monitoring indicator. Some of TKIs can cause severe QT interval prolongation and even sudden death, so we need to adjust the dose according to the individual patient's QT interval. In this paper, we reviewed the related literature and the FDA drug instructions, and analyzed the clinical trials focusing the effects of listed TKIs on QT interval and dosage adjustment. The risks of such drugs have been better understood via the summary of the previous experimental results, and it would play a guiding role to TKIs clinical treatments.

Key words: interval prolong, tyrosine kinase inhibitors, heart rate corrected QT interval, drug safety

CLC Number:

YUAN Dian, YU Guo, WANG Daxin. Advances in effects of tyrosine kinase inhibitors on QT interval and its clinical significance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 825-830.

References

［1］Ederhy SL, Cohen A, Dufaitre G, et al. QT interval prolongation among patients treated with angiogenesis inhibitors［J］. J Target Oncol, 2009, 4(2): 89-99.
［2］Simon WR, Justin CH, Darby JS, et al. Detailed analysis of the impact of age on the QT interval［J］. J Geriatric Cardiol, 2016, 13(9): 740-748.
［3］Van RW, Van GT, Mathijssen RH, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective ［J］. J Lancet Oncol, 2014, 15: e315-e326.
［4］Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable riskfactors［J］. J Medicine (Baltimore), 2003, 82(4): 282-290.
［5］Food and Drug Administration. Axitinib: indications and usage, clinical pharmacology［EB/OL］ .［2014-08-01］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202324s002lbl.pdf.
［6］Sonnichsen D, Dorer DJ, Cortes J, et al. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies［J］. J Cancer Chemother Pharmacol, 2013, 71(6): 1599-1607.
［7］Food and Drug Administration. Ponatinib: indications and usage, clinical pharmacology ［EB/OL］.［2016-11-28］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf.
［8］Food and Drug Administration. Afatinib: indications and usage,clinical pharmacology ［EB/OL］.［2016-10-04］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201292s010lbl.pdf.
［9］Food and Drug Administration. Bosutinib: indications and usage,clinical pharmacology, clinical trials experience ［EB/OL］.［2016-11-17］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203341s006lbl.pdf.
［10］Abbas R, Hug BA, Leister C, et al. A randomized crossover, placebo-and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects ［J］. J Int J Cancer, 2012, 131(3): E304-E311.
［11］Food and Drug Administration. Cabozantinib: indications and usage, cardiac electrophysiology［EB/OL］.［2016-05-20］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203756s002lbl.pdf.
［12］Food and Drug Administration. Regorafenib: indications and usage,pharmacodynamics［EB/OL］.［2016-08-26］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203085s006lbl.pdf.
［13］Food and Drug Administration. Ruxolitinib: indications and usage, clinical pharmacology ［EB/OL］.［2016-03-10］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202192s012lbl.pdf.
［14］Punwani N, Yeleswaram S, Chen X, et al. Evaluation of the effect of ruxolitinib on cardiac repolarization: a thorough QT study ［J］. J Clin Pharmacol Drug Dev, 2014, 3(3): 207-214.
［15］Food and Drug Administration. Sorafenib: indications and usage, warnings and precautions, clinical pharmacology［EB/OL］.［2013-11-22］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021923s016lbl.pdf.
［16］Food and Drug Administration. Lapatinib: indications and usage, warnings and precautions, clinical pharmacology［EB/OL］.［2015-03-31］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022059s020lbl.pdf.
［17］Food and Drug Administration. Cobimetinib: indications and usage,pharmacodynamics ［EB/OL］.［2016-05-31］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206192s001lbl.pdf.
［18］Food and Drug Administration. Ceritinib: indications and usage and warnings and precautions clinical pharmacology［EB/OL］.［2016-09-07］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205755s006lbl.pdf.
［19］Food and Drug Administration. Dasatinib: indications and usage, warnings and precautions, clinical trials experience, pharmacodynamics［EB/OL］.［2016-09-27］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021986s018lbl.pdf.
［20］Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors ［J］. J Cancer, 2010, 116(6): 1582-1591.
［21］Food and Drug Administration. Osimertinib: indications and usage, dose modifications, warnings and precautions ［EB/OL］.［2016-09-28］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208065s003lbl.pdf.
［22］Food and Drug Administration. Nilotinib: indications and usage, dosage and administration, contraindications, warnings and precautions, drug interactions, hepatic impairment, adverse reactions, drug interactions, pharmacokinetics ［EB/OL］.［2017-02-21］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s024lbl.pdf.
［23］Food and Drug Administration. Crizotinib: indications and usage and dose modification and warnings and precautions and clinical trials experience and pharmacodynamics ［EB/OL］.［2017-01-24］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s020lbl.pdf.
［24］Food and Drug Administration. Lenvatinib: indications and usage, warnings and precautions, dose modifications, clinical trials experience, pharmacodynamics ［EB/OL］.［2016-05-13］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206947s003lbl.pdf.
［25］Shumaker RC, Zhou M, Ren M, et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers ［J］. J Cancer Chemother Pharmacol, 2014, 73(6): 1109-1117.
［26］Food and Drug Administration. Pazopanib: indications and usage, warnings and precautions, pharmacodynamics［EB/OL］.［2016-08-05］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022465s023lbl.pdf.
［27］Heath EI, Infante J, Lewis LD, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors ［J］. J Cancer Chemother Pharmacol, 2013, 71(3): 565-573.
［28］Food and Drug Administration. Sunitinib: indications and usage, warnings and precautions, clinical pharmacology［EB/OL］.［2015-11-16］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021938s031lbl.pdf.
［29］Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib ［J］. J Clin Cancer Res, 2009, 15(22): 745-752.
［30］Food and Drug Administration. Trametinib: indications and usage, adverse reactions ［EB/OL］.［2017-02-24］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204114s006lbl.pdf.
［31］Flaherty L, Hamid O, Linette G, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the united states ［J］. J Cancer J, 2014, 20(1): 18-24.
［32］Food and Drug Administration. Vemurafenib: indications and usage, dose modifications, warnings and precautions, clinical pharmacology ［EB/OL］.［2016-08-31］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202429s009lbl.pdf.
［33］Food and Drug Administration. Vandetanib: indications and usage, dosage and administration, contraindications, warnings and precautions, clinical studies experience, drug interactions, clinical pharmacology, pharmacokinetics ［EB/OL］.［2016-07-28］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022405s010lbl.pdf

[1]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[2]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[3]	LOU Anqi, YU Junxian, CHENG Zizhao, SU Qiang. Bruton tyrosine kinase inhibitors and refractory mantle cell lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 680-686.
[4]	CHANG Qingqing, PENG Ying, WANG Guangji, SUN Jianguo. Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 948-956.
[5]	XIE Hai-tang, BARTON Cobert, SUN Rui-yuan. Drug safety registries-are they useful? [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 1-4.
[6]	LI Zhe, YUAN Shou-Jun. Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 361-364.